2009 Annual Report - CRH
2009 Annual Report - CRH
2009 Annual Report - CRH
- TAGS
- annual
- www.crh.com
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
33. Related Party Transactions<br />
The principal related party relationships requiring disclosure in the Consolidated Financial Statements of the Group under<br />
IAS 24 Related Party Disclosures pertain to: the existence of subsidiaries, joint ventures and associates; transactions with<br />
these entities entered into by the Group; and the identification and compensation of key management personnel.<br />
Subsidiaries, joint ventures and associates<br />
The Consolidated Financial Statements include the financial statements of the Company (<strong>CRH</strong> plc, the ultimate parent) and<br />
its subsidiaries, joint ventures and associates as documented in the accounting policies on pages 66 to 71. The Group’s<br />
principal subsidiaries, joint ventures and associates are disclosed on pages 124 to 129.<br />
Sales to and purchases from, together with outstanding payables to and receivables from, subsidiaries and joint ventures<br />
are eliminated in the preparation of the Consolidated Financial Statements (either in full or to the extent of the Group’s<br />
interest) in accordance with IAS 27 Consolidated and Separate Financial Statements and IAS 31 Interests in Joint Ventures.<br />
The amounts in respect of joint ventures are immaterial in the context of the year-end <strong>2009</strong> financial statements. Loans<br />
extended by the Group to joint ventures and associates (see note 15) are included in financial assets (whilst the Group’s<br />
share of the corresponding loans payable by joint ventures is included in interest-bearing loans and borrowings due to the<br />
application of proportionate consolidation in accounting for the Group’s interests in these entities). Sales to and purchases<br />
from associates during the financial year ended 31st December <strong>2009</strong> amounted to €17 million (2008: €17 million) and €458<br />
million (2008: €584 million) respectively. Amounts receivable from and payable to associates (arising from the aforementioned<br />
sales and purchases transactions) as at the balance sheet date are included as separate line items in notes 18 and 19 to<br />
the Consolidated Financial Statements.<br />
Terms and conditions of transactions with subsidiaries, joint ventures and associates<br />
In general, the transfer pricing policy implemented by the Group across its subsidiaries is market-based. Sales to and<br />
purchases from other related parties (being joint ventures and associates) are conducted in the ordinary course of business<br />
and on terms equivalent to those that prevail in arm’s-length transactions. The outstanding balances included in receivables<br />
and payables as at the balance sheet date in respect of transactions with associates are unsecured and settlement arises in<br />
cash. No guarantees have been either requested or provided in relation to related party receivables and payables. Loans to<br />
joint ventures and associates (the respective amounts being disclosed in note 15) are extended on normal commercial terms<br />
in the ordinary course of business with interest accruing and, in general, paid to the Group at predetermined intervals.<br />
Key management personnel<br />
For the purposes of the disclosure requirements of IAS 24, the term “key management personnel” (i.e. those persons having<br />
authority and responsibility for planning, directing and controlling the activities of the Company) comprises the Board of<br />
Directors which manages the business and affairs of the Company. As identified in the <strong>Report</strong> on Directors’ Remuneration<br />
on pages 51 to 59, the Directors, other than the non-executive Directors, serve as executive officers of the Company. Full<br />
disclosure in relation to the <strong>2009</strong> and 2008 compensation entitlements of the Board of Directors is provided in the <strong>Report</strong><br />
on Directors’ Remuneration with disclosure of the share-based payment expense relating to the Board of Directors provided<br />
in note 7 to the Consolidated Financial Statements. Other than these compensation entitlements, there were no other<br />
transactions involving key management personnel.<br />
34. Board Approval<br />
The Board of Directors approved and authorised for issue the financial statements on pages 62 to 115 in respect of the year<br />
ended 31st December <strong>2009</strong> on 1st March 2010.<br />
<strong>CRH</strong> 115